Youxin Technology (YAAS) closed a public offering for gross proceeds of $6 million. The underwriter partially exercised its overallotment option, buying 6.43 million warrants, according to a statement.

The stock fell 27% as intraday volume topped 38.5 million shares, compared with the daily average of almost 3.83 million.

Summit Therapeutics (SMMT) said Sunday that data from a Phase 3 trial of its investigational antibody ivonescimab, combined with chemotherapy, showed "consistent, clinically meaningful improvement" in progression-free survival for patients with certain types of metastatic non-squamous non-small cell lung cancer.

A report from medical news outlet Stat News said the company update showed that patients treated with the drug candidate in North America and Europe experienced faster disease progression than those treated in China.

This "discordant" result may complicate the company's plans to secure approval of the drug candidate in the US and Europe, Stat News said.

The shares slumped 26% as volume topped 12.6 million versus the daily average of 3.33 million.

Price: 0.08, Change: -0.03, Percent Change: -26.73